A high rate of genetic mutations within a tumor, known as high tumor mutation burden (TMB), was only useful for predicting clinical responses to immune.
The Radiosurgery Society® Expands Sponsorship Alliance to Include Physician Groups with First Asian Physician Group Sponsor
Share Article
JunXin Physician Team - Foshan Group
We are very honored to be the first physician group sponsor of the RSS, where we can learn from our experienced colleagues and better serve our patients in Asia. SAN JOSE, Calif. (PRWEB) March 15, 2021
The Radiosurgery Society (RSS), a non-profit medical society dedicated to advancing the science and clinical practice of radiosurgery, today announced that JunXin Oncology Group in China has joined the RSS Sponsorship Alliance as the first Asian Physician Group, adding to the list of highly respected institutions, organizations, societies and corporations to support the advancement of stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT) and advancing therapies.
Study finds high tumor mutation burden predicts immunotherapy response in some, but not all, cancers eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
Commemorating the Contributions of Cancer Research Greats
March 12, 2021, by Norman E. Sharpless, M.D.
Dr. Emil Freireich, who died in February 2021, working with a blood cell separator at MD Anderson Cancer Center.
Credit: National Cancer Institute
There are those moments, those events that make it the ideal time to stop and reflect on the past.
Such is the case with the passing of Dr. Emil Freireich, who died last month at the age of 93 in Houston, his long-time home. Having begun his career in the 1950s at NCI, Dr. Freireich went on to become one of the most accomplished physician–scientists to ever step into a lab or comfort a worried patient.